Guidance for licensing electronic cigarettes and other inhaled nicotine-containing products as medicines

AI Summary

This regulatory guidance issued by the UK Medicines and Healthcare products Regulatory Agency (MHRA) provides a comprehensive framework for licensing nicotine-containing products (NCPs), such as e-cigarettes, as medicinal treatments for smoking cessation. The document outlines the transition from consumer-grade products to licensed medicines under the Human Medicines Regulations 2012 and the UK Medical Device Regulations 2002. Applicants are directed to follow specific legal pathways, such as Regulation 51 or 52, depending on whether their product is a generic or hybrid version of an established therapy like the Nicorette 15 mg Inhalator. Key compliance issues and technical challenges addressed include the purity of the nicotine substance, the safety of flavoring components, and the physical robustness of the delivery device. Specifically, manufacturers must mitigate risks associated with thermal decomposition—such as the production of formaldehyde—and ensure that heating elements do not shed metallic particles. To obtain a marketing authorization, companies are required to: 1) Provide pharmacokinetic data demonstrating that nicotine delivery is effective yet safer than combustible cigarettes; 2) Adhere to Good Manufacturing Practice (GMP) standards at all production and active substance sites; 3) Secure UKCA or CE markings for reusable device components; and 4) Submit a detailed Risk Management Plan and conduct user testing for patient information leaflets. The MHRA provides an accelerated 150-day assessment timeline for high-quality applications to facilitate the entry of safe, effective medicinal e-cigarettes into the UK market.